Dr. Liane Orlee Dallalzadeh, MD

Dr. Dallalzadeh practices at Children's Hospital Los Angeles in Los Angeles, California, part of Children's Hospital Los Angeles.

Dr. Dallalzadeh's NPI, 1699262394, was assigned on April 18, 2018. Dr. Dallalzadeh graduated from Harvard Medical School in 2018. Dr. Dallalzadeh holds Texas license U2185.

Dr. Dallalzadeh's primary practice is Children's Hospital Los Angeles, at 4650 Sunset Blvd, MS 108, Los Angeles, CA 90027 in Los Angeles County. The practice phone is (323) 669-2164.

Dr. Dallalzadeh's primary practice is Children's Hospital Los Angeles in Los Angeles, California, part of Children's Hospital Los Angeles. Dr. Dallalzadeh is also affiliated with Keck Hospital of USC. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Dallalzadeh to 1 more hospital, 2 group practices and clinics, 2 medical groups and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dallalzadeh practices, 6 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Dallalzadeh's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dmand AI has Dr. Dallalzadeh's licenses on file in 2 states: Texas and California.

Dmand AI lists eyelid inflammation and vision problems among the conditions Dr. Dallalzadeh treats.

CMS data shows 39 Medicare services from Dr. Dallalzadeh across 3 procedure codes in 2024, for 40 Medicare patients. Medicare paid $1,824 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 40 Medicare patients who saw Dr. Dallalzadeh in 2024. The largest group is under 65, with 16 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 45% are also on Medicaid. Their average risk score is 2.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dallalzadeh's median patient age at 56, with 56% women.

In 2024, Dr. Dallalzadeh wrote 487 Medicare Part D claims for 229 patients. 97% of them were for generic drugs. CMS names the drug for 445 of them, across 8 drugs with 11 or more claims each, at $6,329 in total drug cost. In 2023, CMS named 153 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Dallalzadeh for performance year 2024, reported as part of a group. Dr. Dallalzadeh accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 13 papers to Dr. Dallalzadeh, published from 2018 to 2025. 2021 was the busiest year, with 3. The most frequent topics are Antibodies, Monoclonal, Humanized, Eyelids and Graves Ophthalmopathy. Dr. Dallalzadeh has published most often in Orbit. Dr. Dallalzadeh's most frequent co-authors are Don O. Kikkawa, MD, Bobby S. Korn, MD and Daniel James Ozzello, MD.

CMS Open Payments shows 21 general payments to Dr. Dallalzadeh from 7 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. Alcon Laboratories Inc paid the most, $807.

Dmand AI lists 11 awards for Dr. Dallalzadeh, most recently Daniel C. Tosteson Scholar in 2016.

Dr. Dallalzadeh graduated from Harvard Medical School in 2018. Dr. Dallalzadeh is a member of AAO.

Dr. Dallalzadeh is in network with 22 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.